Neonates are particularly vulnerable to infections, in part because of the incomplete development of their immune system. Recent advances in immunostimulatory treatments based on conserved microbial components led us to assess the potential of oligodeoxynucleotides (ODNs) for decreasing the sensitivity of neonates to Cryptosporidium parvum infection.
Neonates are particularly susceptible to infections. It is generally accepted that this susceptibility is due to the small number of immune cells present in peripheral lymphoid tissues in early life, as well as to developmental defects in immune function, particularly a delay in the maturation of effective Th1 cell responses. Recent evidence from mouse models suggests that adjuvants such as CpG oligodeoxynucleotides (ODNs) can induce strong Th1 immune responses in neonates and upregulation of crucial costimulatory molecules by dendritic cells [1, 2] .
ODNs bearing unmethylated CpG motifs can mimic the immunostimulatory effects of bacterial DNA and can be synthesized on either a phosphodiester backbone or a phosphorothioate backbone, the latter being more resistant to nuclease degradation. CpG ODNs interact with Toll-like receptor 9 (TLR9) in the endoplasmic reticulum and trigger signaling pathways that activate various transcription factors, including NF-kB and activation protein-1 [3] . This leads to B cell proliferation and production-by monocytes/macrophages, B cells, and dendritic cells-of the cytokines interleukin (IL)-12, IL-6, and tumor necrosis factor (TNF)-a, as well as costimulatory molecules [4] [5] [6] . Although subcutaneous or intraperitoneal (ip) injection of CpG ODNs has shown potential in increasing resistance to several infectious diseases, only very limited studies have investigated the efficacy of oral administration in adult animals, and such studies have not yet been performed in neonates [7] [8] [9] [10] . We evaluated the immunostimulant effect of oral CpG ODN treatment on the innate immune system of neonates by challenging mice with Cryptosporidium parvum. This zoonotic protozoan parasite infects intestinal epithelial cells and causes acute watery diarrhea and weight loss in young or immunodeficient hosts [11] . In the mouse model of infection, the severity of the disease is strongly related to immune status and to the effective development of a protective Th1 immune response [12, 13] . This has been clearly demonstrated in vivo by interferon (IFN)-g or IL-12 neutralization and in mice deficient for these cytokines [14] [15] [16] [17] . The data reported in the present study show that both oral and ip administration of phosphorothioate ODNs to neonate mice leads to a large decrease in C. parvum parasite load.
MATERIALS AND METHODS
Mice. C57BL/6J and IFN-g-deficient C57BL/6J-Ifg tml mice (GKO) were purchased from Jackson Laboratories. BALB/cByJ mice were purchased from Charles River Laboratories. TLR9-deficient mice and wild-type control mice (129Ola ϫ C57BL/ 6) were maintained at Institut National de la Recherche Agronomique (Jouy en Josas) facilities. The dams with their litters were housed individually in cages under pathogen-free conditions, with food and water available ad libitum. C57BL/6 adult GKO mice are susceptible to infection with C. parvum and stay chronically infected, and they do not feed their pups, whereas their wild-type counterparts are resistant to the infection. Therefore, experiments with GKO neonates were performed after cross-fostering of 1-day-old GKO neonates with wild-type C57BL/6 mothers. The study was conducted in accordance with animal-experimentation guidelines (06.09.2001) of the Federation of European Laboratory Animal Science Associations and was approved by the local institutional ethics committee.
Parasites and reagents. C. parvum oocysts were initially isolated from the feces of an infected child and were maintained by regular passages in neonate calves [18] . Oocysts were !1 month old when used as an inoculum. Phosphorothioate-stabilized ODNs or phosphodiester ODNs were purchased from Sigma Genosys (table 1) . If not specified in the text, all ODNs used are phosphorothioate stabilized for all bases.
ODN treatments and C. parvum infection. Neonates (1-2 days old) were pretreated with 100 mg of ODNs given orally with animal feeding needles (Harvard Apparatus) in a 2.5-mL volume or ip in a 20-mL volume. Control mice were mockadministered a similar volume of PBS. The next day, the neonates were inoculated orally with 10 6 oocysts. In other experiments, the treatment was administered 1 day after infection with C. parvum. Mice were killed by cervical dislocation at different times after inoculation. Parasite load determination. The level of infection in neonate mice is expressed by the number of oocysts in the intestine. Because infection does not always spread homogeneously along the intestine, the intestines were removed in their entirety, weighed, and individually crushed in 1 mL of water with a homogenizer (Ultra-turrax). Oocysts were quantified in blinded samples in Sheather's solution on a hemacytometer, using light microscopy.
RNA extraction and quantitative real-time polymerase chain reaction (PCR). Neonates were killed after 4 or 24 h of stimulation with ODNs or mock treatment with PBS. The removed ilea were homogenized in TRIzol (Gibco-BRL Life Technologies) with an Ultra-turrax. Purified RNA free of genomic DNA contamination was reverse transcribed and amplified by PCR. We quantified mRNA in triplicate for various cytokine genes, by SYBR Green incorporation using an iCycler thermocycler (Bio-Rad). Hypoxanthine phosphoribosyltransferase mRNA expression was analyzed for every target sample, to normalize for RNA quantification and efficiency in cDNA synthesis. Primer sequences are available from the authors on request. The data are presented as the ratio of the target gene expression in CpG ODN 1668-treated or non-CpG ODN 1668-treated mice to the target gene expression in mock-treated mice.
Statistical analysis. The Kruskal-Wallis nonparametric test was used to compare the different groups. In the case of significant differences between groups, as indicated by analysis of variance, multiple comparisons of groups were made, in accordance with methods described by Siegel and Castellan [19] . The level of significance was set at . P ! .05
RESULTS
Strong decrease in parasite load at day 6 after C. parvum infection following a single oral administration of CpG ODNs or non-CpG ODNs. We first tested the immunostimulant properties of CpG ODNs in the absence of a specific antigen on the neonatal mucosal immune system of 2 strains of mice with different T helper orientations, C57BL/6 (Th1 type) and BALB/c (Th2 type). These mice show similar kinetics of C. parvum infection, although, compared with C57BL/6 neonates, BALB/c neonates are more heavily infected at the peak of infection (day 9 after infection) (figure 1A). A single oral administration of ODNs to neonate mice was performed 1 day after birth, followed 24 h later by a challenge with 10 6 oocysts of C. parvum. After treatment of C57BL/6 neonates with CpG ODN 1668, a large reduction, of 92%, in the number of oocysts present in the intestine was observed at day 6 after infection (figure 1B). BALB/ c neonates pretreated orally with CpG ODN 1668 showed a similar level of reduction in the number of oocysts at day 6 after infection, compared with infected untreated neonates (91%;
, Kruskal-Wallis test [data not shown]).
Surprisingly, non-CpG ODN 1668 was as effective as CpG ODN 1668 in reducing C. parvum infection (figure 1B). Both treatments require a single-administration dose of 100 mg. Lower doses did not significantly control parasite development (data not shown). However, still significant, the effect of a single oral pretreatment with CpG ODN 1668 or non-CpG ODN 1668 was reduced at the peak of parasite excretion (day 10) (figure 1B). We reevaluated the unusual result seen for non-CpG ODN 1668, using 2 other oligonucleotides-CpG ODN 1826 and non-CpG ODN 1982-that are commonly used in mice [9, 10, 20] . These ODNs were as effective as CpG ODN 1668 and nonCpG ODN 1668 in reducing C. parvum multiplication in both C57BL/6 and BALB/c mice. At day 6 after infection, the number of oocysts in the intestines of C57BL/6 mice was reduced by 80% with CpG ODN We also investigated the effect of the ODN backbone in C57BL/6 neonates. These mice were pretreated orally with 100 mg of phosphodiester ODN (ODN-PO), CpG ODN-PO 1668, or non-CpG ODN-PO 1668 1 day before infection. Only CpG ODN-PO 1668 significantly reduced the parasite load, by 53%, Figure 2 . Effect of intraperitoneal (ip) pretreatment on Cryptosporidium parvum infection in C57BL/6 neonatal mice. Two-day-old C57BL/6 neonates were treated by the ip route with CpG oligodeoxynucleotide (ODN) 1668 (black box) or non-CpG ODN 1668 (striped box) or mock-treated with PBS (white box) and were infected the next day. C. parvum oocysts were quantified at day 6 after infection. The graphical representation of data is as described in figure 1 .
for each group at each time point n у 12 (* , Kruskal-Wallis test; NS, nonsignificant). The percentage on top P ! .05 of the black bar represents the decrease of parasite load in treated vs. mock-treated neonates. Data are representative of 3 experiments with similar results. Induction of a strong and extended inhibition of parasite multiplication by repeated oral administration of ODNs. First, we administered CpG ODN 1668, non-CpG ODN 1668, or non-CpG ODN 1982 orally to C57BL/6 neonates on the day after infection and, therefore, in presence of C. parvum antigens. The number of oocysts in the ileum was reduced by 190% at day 6 after infection ( figure 1C ). This suggests that treatment of an ongoing infection is as efficient as oral pretreatment with ODNs in controlling C. parvum multiplication. In addition to pretreatment of C57BL/6 neonates on the day before infection, we administered further treatment with either CpG ODN 1668 or non-CpG ODN 1668 during the course of infection. We found an excellent and extended control of parasite multiplication with this continued treatment ( figure 1D) .
Requirement of the presence of a CpG motif for the decreased parasite load conferred by intraperitoneal ODN administration. Our data show-for the first time, to our knowledge-a decrease in a neonatal parasite load, caused by oral administration of a non-CpG ODN. Therefore, we investigated whether such an effect was restricted to oral administration. Following the same protocol as that used for oral administration, we investigated the effect that ip administration of CpG ODN 1668 and non-CpG ODN 1668 has on parasite multiplication. The level of protection of neonates that was conferred by ip treatment was as good as that conferred by oral treatment; however, the ODN requires a CpG motif (figure 2).
TLR9-independent effect of oral administration of non-CpG ODN 1668 on C. parvum multiplication. Using mice deficient for TLR9, we investigated whether the effect on C. parvum multiplication seen after oral administration of CpG ODNs and non-CpG ODNs requires specific activation of this receptor. In 3 independent experiments, we observed a significant decrease in parasite load, of 70%-92%, 6 days after oral administration of non-CpG ODN 1668, whereas a consistent but nonsignificant decrease was observed after oral administration of CpG ODN 1668 ( figure 3A) . This suggests that, after oral administration, non-CpG ODN 1668 acts by a TLR9-independent mechanism, whereas CpG ODN 1668 acts mainly by a TLR9-dependent mechanism. Consistent with previous studies, the effect of ip administration of CpG ODN 1668 on parasitic load was TLR9 dependent (figure 3B).
Differences in ileal cytokine responses, depending on the nature of the ODN and the route of administration. To clarify whether the decrease in parasite load observed after ODN administration is associated with the up-regulation of a specific set of cytokines, we analyzed, by real-time PCR, the level of expression of these molecules in the ileum of C57BL/6 neonates at 4 and 24 h after the treatment administered at 1 day of age. Both oral and ip administration of CpG ODN 1668 induce a rapid and strong up-regulation of proinflammatory cytokines (IL-6 and IL-1b), of Th1 cytokines (IL-12p40 and IFN-g), of the Th2 cytokine IL-10 (but not IL-4; data not shown), and of chemokine monocyte chemotactic protein-3 in the ileum of neonates ( figure 4A and 4B ). Four hours after treatment, differences in IFN-g, IL-6, and IL-10 mRNA up-regulation were observed between mice that had received oral ODN administration and those that had received ip ODN administration. This suggests that the nature and proportion of the cell populations responding to CpG ODN 1668 may differ depending on the administration route ( figure 4A and 4B) . Orally administered non-CpG ODN 1668 did not induce more than a 5-fold up-regulation of the cytokine mRNA levels at 4 h after infection (figure 4A). After ip administration of non-CpG ODN 1668, some cytokine mRNAs were up-regulated, although much less than they were when CpG ODN 1668 was administered (figure 4B). At 24 h after treatment, the up-regulation of most of the cytokine mRNAs, except IL-10, was reduced or had returned to basal levels ( figure 4C and 4D) .
Induction of strong up-regulation of CD69 mRNA by oral administration of CpG ODN 1668 but not non-CpG ODN 1668. CD69 expression is commonly used to study early activation of T, B, and NK cells. There are too few immune cells present in the mucosa of neonate mice to study the expression of the early-activation antigen CD69 by flow-cytometric or immunohistochemical methods. Therefore, we used quantitative real-time reverse-transcription PCR to evaluate the effect of treatment on the expression of this early activation marker. We observed a 1100-fold increase in CD69 mRNA levels in the ileum of C57BL/6 neonates 4 h after oral or ip administration of CpG ODN 1668 (figure 5). The levels of CD69 mRNA had returned to basal levels 24 h after treatment. Compared with CpG ODN 1668, non-CpG ODN 1668 induced only small changes in CD69 mRNA levels in the ileum, no matter which administration route was used (figure 5).
Requirement for IFN-g in the reduction of C. parvum infection induced by oral treatment with both CpG ODN 1668 and non-CpG ODN 1668. IFN-g is a key component of the immune response to C. parvum infection [21] . Oral administration of CpG ODN 1668 or non-CpG ODN 1668 to GKO neonates before C. parvum infection induced a consistent but nonsignificant small decrease in the number of oocysts present in the intestines at day 6 after infection in 2 independent experiments ( figure 6 ). This suggests that both TLR9-dependent and TLR9-independent mechanisms induced by CpG ODN 1668 or non-CpG ODN 1668 require, at 1 point, the presence of IFN-g to significantly reduce the parasite load.
DISCUSSION
Immune responses to intracellular pathogens like C. parvum require the development of a Th1-type response with the production of IFN-g and IL-12. The capacity of CpG ODNs to promote a Th1-biased immune response is well known in adult animals [22] . Although a few studies report the use of CpG ODNs by the oral route in adult animals, oral administration to neonates had not been previously investigated [8] [9] [10] 23] . In the present study, we examined the effect of both oral and ip administration of ODNs before and during an ongoing infection with C. parvum.
A single oral administration of phosphorothioate CpG ODN 1668 before C. parvum infection induced a large decrease in parasite multiplication at day 6 after infection, although, at later time points, the level of protection was reduced. Treatment administered the day after infection-and, therefore, in presence of C. parvum antigens-also efficiently controlled infection at day 6 after infection. As expected, the combination of pretreatment and repeated oral administration during infection resulted in an effective and persistent control of the parasite load. This effect was independent of the T helper orientation of mouse strains, since similar data were obtained with Th2-biased BALB/c and Th1-biased C57BL/6 mice.
Unexpectedly, non-CpG ODN 1668 was shown to control C. parvum infection. Two other ODNs, CpG ODN 1826 and non-CpG ODN 1982, also had similar effects on both strains of mice, suggesting that the level of protection induced by nonCpG ODN 1668 was not restricted to this particular ODN. In the only publication studying the effect of an intragastric administration of CpG ODNs on the development of an infectious disease, Raghavan et al. reported that ODN 1982, which lacks CpG motifs, gave no protection against Helicobacter pylori development [10] . This difference may be due to the nature and the location of the infection, the age of the animals used (adult vs. neonate), or a different administration dose used in the 2 studies.
We then investigated whether the particular effect of non-CpG ODN 1668 would occur if the pretreatment was administered by the ip route. Interestingly, we found that this administration route also provided excellent control of the infection but, unlike oral administration, the protective effect occurred only when a CpG motif was present in the ODN. Hemmi et al. showed that the cellular response to CpG ODNs depends on the presence of TLR9 [24] . We confirmed the necessary interaction of the CpG motif with TLR9 in reducing the level of C. parvum infection, by using TLR9-deficient mice inoculated orally or ip with CpG ODN 1668. However, after oral administration, even in the absence of TLR9, C. parvum infection was still controlled by nonCpG ODN 1668, showing that the protective effect after oral administration is TLR9 independent. In addition to the sequence, the structure of the ODN is also important: with a phosphodiester backbone, oral administration of CpG ODN 1668 but not nonCpG ODN 1668 caused a 53% decrease in the C. parvum parasite load at day 6 after infection. This suggests that the effect of nonCpG ODN 1668 on the TLR9-independent mechanism depends on its phosphorothioate backbone.
Intraperitoneal administration of non-CpG ODNs has often been reported to have no effect on the immune response [25, 26] . Nevertheless, a few studies have reported unexpected effects of non-CpG ODNs. Wang et al. showed that non-CpG ODN 1982 associated with an antigen activates specific B lymphocytes. Th2 differentiation has also been observed in 3 other studies in which non-CpG ODNs were administered by the ip or mucosal route in the presence of antigens [23, 27, 28] . In our study, ip or oral administration of CpG ODNs before infection led to a rapid and strong up-regulation of Th1-type (IL-12p40 and IFN-g) and Th2-type (IL-10) cytokines in the ileum of C57BL/6 neonates. By contrast, after oral administration of non-CpG ODN 1668, we observed no strong initial cytokine up-regulation. However, after ip administration of non-CpG ODNs, we observed the up-regulation of certain cytokines, but it was not associated with a decrease in C. parvum parasite load. Nevertheless, this could be explained by a lower level of Th1 cytokine expression, compared with that observed after CpG ODN treatment by the oral or ip route. The level of protection induced by CpG ODNs for other intracellular pathogens, such as Plasmodium falciparum or Listeria monocytogenes, has been shown to depend on the production of IL-12 and IFN-g [29, 30] . Data obtained with IFN-g-deficient neonate mice showed that neither CpG ODN 1668 nor nonCpG ODN 1668, administered orally, was able to significantly decrease the parasite load at day 6 after infection. However, in such experiments, we cannot evaluate the importance that the IFN-g that is produced in direct response to the CpG ODN 1668 administration has in the resolution of the infection. Nevertheless, both the TLR9-dependent and the TLR9-independent mechanisms cannot bypass the IFN-g production needed to control C. parvum infection.
The nature of the responding cells remains speculative. Recruitment of inflammatory cells associated with decreased infection has been reported after CpG ODN administration to mucosal surfaces. For example, the local delivery of CpG ODN 1826 to the genital tract caused significant recruitment of inflammatory cells to the submucosa, associated with the protection of mice from subsequent vaginal herpes simplex virus type 2 challenge [31] . Raghavan et al. noted an enhanced but moderated infiltration of immune cells in the gastric mucosa after intragastric administration of CpG ODN 1826 [10] . Immunohistochemical analyses performed in this study revealed no significant recruitment of inflammatory cells during the first 24 h after a single or repeated administration of CpG ODN 1668 to neonates (data not shown). It has to be noted that, during the first days of life, the mouse intestine is not fully developed. At homeostasis, there are only a very limited number of intraepithelial lymphocytes and other immune cells in the lamina propria, and the Peyer patches are poorly developed. Nevertheless, we showed previously that neonates can recruit inflammatory cells to the mucosa after C. parvum infection [32, 33] . Neonates may not recruit inflammatory cells as efficiently as adults when the proinflammatory signal is transient. However, increased CD69 mRNA expression showed that cells were activated in the ileum. Among the T, B, and NK cells that express CD69, only B cells can be directly activated by CpG ODNs [34, 35] . Therefore, in response to CpG ODN 1668 administration, B cells may be the first to up-regulate CD69, followed by indirect activation of T cells and NK cells by dendritic cells producing IL-12 [36] . As with CpG ODN administration, non-CpG ODN administration induced no significant recruitment of inflammatory cells. Without obvious cell recruitment (data not shown), the mechanism by which orally inoculated non-CpG ODN 1668 decreases C. parvum parasite load remains unknown. Experiments are currently under way to determine this mechanism, with a particular emphasis on intestinal epithelial cell turnover and apoptosis.
In summary, we have demonstrated that ODN stimulation of the neonatal innate immune system allows very effective control of C. parvum infection by 2 different mechanisms that require, at one point, the presence of IFN-g. Moreover, our data show-for the first time, to our knowledge-control of an infection by treatment with non-CpG ODNs. The optimization of such an oral adjuvant that is active in the absence of apparent toxicity may be extremely useful for the treatment of cryptosporidiosis and other neonatal enteric diseases. However, much more work needs to be done on ODN treatments before they can be safely used in therapy.
